Isophenoxodiol

Summary

Isophenoxodiol (CHEMBL195560) is a phase-3 clinical-stage small molecule; indicated across 5 conditions including peritoneal neoplasm and fallopian tube neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 5 conditions
• Clinical trials: 3
• Chemistry: 240.25 Da · C15H12O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL195560
Name	Isophenoxodiol
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	11356877
Molecular formula	C15H12O3
Molecular weight	240.25
InChIKey	QCNUDDPWPNUALZ-UHFFFAOYSA-N

SMILES: C1C2=C(C=C(C=C2)O)OC=C1C3=CC=C(C=C3)O

IUPAC name: 3-(4-hydroxyphenyl)-4H-chromen-7-ol

Also known as: Isophenoxodiol, Phenoxodiol, ISOPHENOXODIOL

Patent coverage: 9 distinct patent families (12 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 11 (92%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Estrogen receptor beta, Estrogen receptor.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P06211	6.63	IC50	234.4	nM	CHEMBL_ACT_8059212
ESR2	6.17	IC50	680	nM	CHEMBL_ACT_1506676
ESR2	6.17	IC50	680	nM	CHEMBL_ACT_1506677
ESR2	6.17	IC50	680	nM	CHEMBL_ACT_16317171
ESR2	6.17	IC50	680	nM	CHEMBL_ACT_26578241

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
peritoneal neoplasm	3	MONDO:0006901	EFO:1001100
fallopian tube neoplasm	3	MONDO:0021092	MONDO:0002158
ovarian cancer	3	MONDO:0008170	MONDO:0008170

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	1
PHASE1/PHASE2	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00382811	PHASE3	COMPLETED	OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
NCT00091377	PHASE1/PHASE2	COMPLETED	Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
NCT00557037	PHASE2	COMPLETED	A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Prostate Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).